Skip to main content
Evidence Snapshot

Serine/threonine-protein kinase TBK1

CHEMBL5408 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5408
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase TBK1 as ChEMBL target CHEMBL5408, mapped to UniProt Q9UHD2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase TBK1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5408
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9UHD2
Serine/threonine-protein kinase TBK1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serine/threonine-protein kinase TBK1 matters

As of 2026-09-14

Serine/threonine-protein kinase TBK1 is reviewed as Serine/threonine-protein kinase TBK1 (UniProt Q9UHD2); the current evidence base includes 14 approved drugs, 4275 compounds, and 431 assays, with lead potency reaching pChEMBL 10.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 14 approved drugs, 4275 compounds, and 431 assays for this target. The dominant activity type is IC50. CHEMBL3604928 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL3604928 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
14 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serine/threonine-protein kinase TBK1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9UHD2, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4275
Total Compounds
431
Total Assays
14
Approved Drugs
IC50: 3856.0, KI: 333.0, EC50: 22.0, KD: 361.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3604928
10.2 IC50
No preferred name
CHEMBL5743492
9.5 IC50
No preferred name
CHEMBL5985679
9.3 IC50
No preferred name
CHEMBL6002719
9.3 IC50
No preferred name
CHEMBL5742193
9.3 IC50

Approved Drugs

Structure Compound First Approval
MOMELOTINIB
CHEMBL1078178
2023
FEDRATINIB
CHEMBL1287853
2019
MIDOSTAURIN
CHEMBL608533
2017
NINTEDANIB
CHEMBL502835
2014
BOSUTINIB
CHEMBL288441
2012
CRIZOTINIB
CHEMBL601719
2011
SUNITINIB
CHEMBL535
2006
AMLEXANOX
CHEMBL1096
1996
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5408